Submit Deal

MERUS B.V.

HQ - Utrecht

Summary

Merus N.V. is a clinical-stage immuno-oncology company focused on developing innovative full-length bispecific antibody therapeutics.

Deals Overview

Total Deals3

Valued Deals2

Total Value£ 5.91 B

Avg. Deal Size£ 2.96 B

Market Context

Senior Management

Bill Lundberg
President and CEO
Sherri Spear
Senior Vice President
Kathleen Farren
Director Investor Relations

Sort

latham & watkins

HQ - New York, United States

legal advisors (2)

2 Shared Deals

2 For

£ 5.90 B

Total Value

weil gotshal and manges

HQ - New York

legal advisors (1)

1 Shared Deal

1 Opposite

£ 15 M

Total Value

ropes & gray

HQ - Boston

legal advisors to financial advisors (1)

1 Shared Deal

1 For

£ 5.90 B

Total Value

jefferies & company

HQ - New York, United States

financial advisors (1)

1 Shared Deal

1 For

£ 5.90 B

Total Value

nautadutilh

HQ - Amsterdam, Netherlands

legal advisors (1)

1 Shared Deal

1 For

£ 5.90 B

Total Value

pjt partners

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 5.90 B

Total Value

kromann reumert

HQ - Copenhagen, Denmark

legal advisors (1)

1 Shared Deal

1 Opposite

£ 5.90 B

Total Value

a&o shearman

HQ - New York, United States

legal advisors (1)

1 Shared Deal

1 Opposite

£ 5.90 B

Total Value

morgan stanley

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 5.90 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy